2022 World Conference on Lung Cancer (Posters)-P1.15-12. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

P1.15-12. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

Back to course

Pdf Summary

A study presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer compared the patient-reported outcomes (PROs) of cemiplimab versus chemotherapy in advanced non-small cell lung cancer (NSCLC) based on PD-L1 levels. The study included patients across three PD-L1 level subgroups: 50% to 60%, 60% to 90%, and 90%.<br /><br />The analysis of PROs showed that cemiplimab resulted in significant overall improvement and delayed time to clinically meaningful deterioration in global health status (GHS)/quality of life (QoL) and multiple patient-reported cancer-related and lung cancer-specific functions and symptoms across multiple PD-L1 50% subgroups.<br /><br />No analyses yielded statistically significant PRO results favoring chemotherapy when comparing the two treatment arms for any European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) or EORTC Quality of Life-Lung Cancer Module (QLQ-LC13) scale.<br /><br />The positive PRO results support the favorable benefit-risk profile of cemiplimab monotherapy compared to chemotherapy in advanced NSCLC across all PD-L1 50% subgroups.<br /><br />The study also showed that cemiplimab resulted in a delay in time to deterioration in GHS/QoL in the PD-L1 90% subgroup, as well as in physical functioning, appetite loss, and dyspnea across multiple PD-L1 subgroups.<br /><br />In conclusion, cemiplimab demonstrated significant improvements in PROs compared to chemotherapy in advanced NSCLC patients across different PD-L1 levels. These findings support the use of cemiplimab as a monotherapy treatment option in this patient population.

Asset Subtitle

Saadettin Kilickap, Turkey

Meta Tag

Speaker Saadettin Kilickap, Turkey

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

cemiplimab

chemotherapy

advanced non-small cell lung cancer

PD-L1 levels

patient-reported outcomes

global health status

quality of life

lung cancer-specific functions

EORTC Quality of Life-Core 30